Lung Diseases

Patients most frequently seeking cell therapy programs present with chronic or residual lung damage accompanied by inflammation, impaired respiratory function, and reduced tissue repair capacity.

The most common conditions include:

• chronic obstructive pulmonary disease (COPD)

• pulmonary emphysema

• pulmonary fibrosis and fibrotic changes of lung tissue

• chronic inflammatory airway diseases

• recovery after severe pneumonia and viral lung injuries

In these cases, cell therapy may be used as part of a comprehensive treatment approach to support regeneration and improve the patient’s quality of life.

In regenerative therapy programs for lung conditions, the most commonly used cell types include:

Donor-derived mesenchymal stromal cells (MSCs) from the umbilical cord or placenta
These cells exhibit strong anti-inflammatory and immunomodulatory effects, help improve microcirculation, and support regenerative processes within lung tissue.

Umbilical cord blood stem cells
These may be used as an adjunct component of therapy to promote regeneration and maintain immune balance.

The cell type, route of administration, and dosage are individually determined following a comprehensive medical assessment of the patient’s condition.

Cell therapy does not replace standard treatment for lung diseases but may serve as an important complementary component.

Potential outcomes include:

• reduction of chronic inflammation

• improved tolerance to physical activity

• support of tissue regeneration

• stabilization of lung function

• improvement of overall well-being

• mitigation of the effects of systemic inflammatory response (“cytokine storm”)

• reduction of pulmonary fibrosis